Innovation in Action: OBI Pharma Sharpens Focus on ADC Products, Platforms, and Out-Licensing
Integrating Product and Platform Capabilities to Drive Global Collaboration

OBI Pharma (4174.TWO) convened its 2025 Annual General Shareholders’ Meeting today (June 27). Chief Executive Officer Dr. Heidi Wang announced that, following the termination of the Globo H programs, the company has pivoted to focus on Antibody-Drug Conjugates (ADCs).  The out-licensing of its ADC products and proprietary platform technologies are the twin pillars driving the next phase of growth.